Study guide
Section 9.1: Diabetes Mellitus & Acute Complications
NCCPA PANCE Physician Assistant Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular System
1.1 Hypertension (Essential & Secondary) 1.2 Coronary Artery Disease & Myocardial Infarction 1.3 Heart Failure & Cardiomyopathy 1.4 Cardiac Arrhythmias & Conduction Disorders 1.5 Valvular Heart Disease 1.6 Vascular Diseases (Aortic Aneurysm, PAD, DVT) 1.7 Congenital Heart Disease (ASD, VSD, PDA, Coarctation, Tetralogy of Fallot)
2 Chapter 2: Pulmonary System
Section 2.1: Asthma & Bronchospastic Disease Section 2.2: Chronic Obstructive Pulmonary Disease (COPD) Section 2.3: Infectious Pulmonary Disorders (Pneumonia & Tuberculosis) Section 2.4: Restrictive, Vascular & Neoplastic Pulmonary Conditions
3 Chapter 3: Gastrointestinal/Nutrition
3.1 Esophageal & Gastric Disorders (GERD, PUD) 3.2 Hepatic, Biliary & Pancreatic Disorders 3.3 Small & Large Bowel Disorders (IBD, Diverticulitis, Obstruction) 3.4 Colorectal Neoplasms & Nutritional Deficiencies
4 Chapter 4: Musculoskeletal System
Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA) Section 4.2: Infectious & Inflammatory MSK Disorders (Osteomyelitis, Septic Arthritis) Section 4.3: Bone & Joint Disorders (Fractures, Osteoporosis, Fibromyalgia) Section 4.4: Spine and Soft Tissue Pathology (Low Back Pain, Tendonitis)
5 Chapter 5: Neurologic System
Section 5.1: Cerebrovascular Disease (Stroke, TIA) Section 5.2: Seizure Disorders & Epilepsy Section 5.3: Demyelinating & Neurodegenerative Diseases Section 5.4: Headache Syndromes & Cranial Nerve Disorders
6 Chapter 6: Psychiatry/Behavioral Science
Section 6.1: Depressive and Bipolar Disorders Section 6.2: Anxiety, Trauma-Related, and Obsessive-Compulsive Disorders Section 6.3: Schizophrenia and Psychotic Disorders Section 6.4: Eating, Substance Use, and Personality Disorders
7 Chapter 7: Infectious Diseases
7.1 Viral Infections (HIV, EBV, Influenza) 7.2 Bacterial & Spirochetal Infections (Sepsis, Meningitis) 7.3 Fungal & Parasitic Infections 7.4 Tick-Borne Diseases (Lyme, Rocky Mountain Spotted Fever)
8 Chapter 8: Reproductive System
8.1 Obstetrics: Normal Pregnancy & Prenatal Care 8.2 Obstetrics: Pregnancy Complications 8.3 Gynecology: Menstruation, Menopause, PCOS, and Vaginal Infections
9 Chapter 9: Endocrine System
Section 9.1: Diabetes Mellitus & Acute Complications Section 9.2: Thyroid Disorders & Goiter Section 9.3: Adrenal & Pituitary Disorders
10 Chapter 10: Eyes, Ears, Nose, and Throat
Section 10.1: Ophthalmic Disorders (Glaucoma, Conjunctivitis, Cataracts) Section 10.2: Otic Disorders (Otitis Media/Externa, Vertigo, Labyrinthitis) Section 10.3: Nose, Sinus, and Throat Complaints (Sinusitis, Pharyngitis, Epiglottitis)
11 Chapter 11: Professional Practice
11.1 Bioethics & Legal Standards (Informed Consent, Autonomy, HIPAA) 11.2 Patient Safety, Quality Improvement, and Communication 11.3 Evidence-Based Medicine & Clinical Practice Guidelines
12 Chapter 12: Hematologic System
Section 12.1: Anemias (Microcytic, Macrocytic, Hemolytic/Sickle Cell) Section 12.2: Coagulation and Bleeding Disorders (ITP, TTP, Hemophilia, vWD) Section 12.3: Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
13 Chapter 13: Renal System
13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD) 13.2 Acid-Base and Electrolyte Disorders 13.3 Glomerular & Tubulointerstitial Diseases
14 Chapter 14: Dermatologic System
Section 14.1: Inflammatory & Autoimmune Skin Conditions Section 14.2: Infectious Skin Conditions Section 14.3: Skin Neoplasms & Burn Management
15 Chapter 15: Genitourinary System
Section 15.1: Male Genitourinary Disorders (BPH, Prostate Cancer, Testicular Torsion, ED) Section 15.2: Urinary Incontinence, Nephrolithiasis, and GU Trauma
Section 9.1: Diabetes Mellitus & Acute Complications
Key Takeaways Explain This Topic AI
Diagnostic criteria for diabetes mellitus require two abnormal tests: HbA1c >= 6.5%, Fasting Plasma Glucose >= 126 mg/dL, or 2-hour OGTT >= 200 mg/dL.
Metformin is first-line for Type 2 Diabetes but is strictly contraindicated in patients with an eGFR < 30 mL/min/1.73m² due to lactic acidosis risk.
SGLT2 inhibitors and GLP-1 agonists offer cardiorenal protection and weight loss benefits, but SGLT2 inhibitors carry a risk of euglycemic DKA.
In DKA and HHS, aggressive fluid resuscitation is the first priority, and insulin must be withheld if the potassium level is below 3.5 mEq/L (2024 adult consensus).
Last updated: October 2026
Diabetes Mellitus & Acute Complications
PANCE High-Yield Focus: Diabetes mellitus and its acute complications are major PANCE blueprint topics. Focus on the diagnostic thresholds for diabetes, distinguishing Type 1 vs. Type 2 pathophysiology, the mechanisms and contraindications of oral hypoglycemics (especially Metformin, SGLT2i, and GLP-1 agonists), and the step-by-step fluid, insulin, and potassium replacement protocols for DKA and HHS.
- Pathophysiology and Presentation
- Type 1 vs. Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease where T-cell mediated destruction of pancreatic beta cells in the islets of Langerhans leads to absolute insulin deficiency. It is strongly linked to HLA-DR3 and HLA-DR4 genes. Common autoantibodies include glutamic acid decarboxylase (anti-GAD65) , islet cell antibodies (ICA) , and insulin autoantibodies (IAA) .
Type 2 Diabetes Mellitus (T2DM) is characterized by peripheral insulin resistance (decreased tissue sensitivity to insulin) combined with a progressive decline in insulin secretion. It is heavily associated with obesity, visceral adiposity, physical inactivity, and metabolic syndrome.
Clinical Presentation
Osmotic Symptoms: Both types present with polyuria, polydipsia, polyphagia, and blurred vision. Weight loss is common in T1DM due to catabolism.
DKA: Rapid onset (under 24 hours), presenting with nausea, vomiting, diffuse abdominal pain, and lethargy. Physical signs include Kussmaul respirations (deep, rapid breathing), a fruity acetone breath odor, and signs of severe dehydration (tachycardia, hypotension).
HHS: Insidious onset (days to weeks), presenting with severe dehydration, confusion, lethargy, focal neurological deficits, or coma. Acidosis is absent, but volume depletion is extreme.
- Diagnostic Criteria and Screening
- Screening and Diagnosis
The ADA recommends screening for asymptomatic adults beginning at age 35, or earlier in overweight patients (BMI >= 25 kg/m², or >= 23 kg/m² in Asian Americans) with risk factors.
A diagnosis of diabetes mellitus requires two abnormal tests from either the same sample or separate encounters. The criteria are:
Fasting Plasma Glucose (FPG): >= 126 mg/dL (after >= 8 hours of fasting).
Hemoglobin A1c (HbA1c): >= 6.5%.
2-hour Oral Glucose Tolerance Test (OGTT): >= 200 mg/dL (using 75g glucose load).
Random Plasma Glucose: >= 200 mg/dL in a patient with classic symptoms of hyperglycemia.
Differentiating T1DM and T2DM Labs
To distinguish these conditions, obtain autoantibody panels (anti-GAD65) and a C-peptide level (a marker of endogenous insulin production):
T1DM: Low or undetectable C-peptide levels.
T2DM: Normal, elevated, or inappropriately normal C-peptide levels.
- Pharmacological Management
- Non-Insulin Antidiabetic Medications
Metformin (Biguanide): First-line agent. It decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity. It is weight-neutral and does not cause hypoglycemia. It is strictly contraindicated in patients with an eGFR < 30 mL/min/1.73 m² due to the risk of lactic acidosis. Hold for 48 hours after iodinated contrast.
SGLT2 Inhibitors (e.g., Empagliflozin): Inhibits sodium-glucose cotransporter 2 in the proximal convoluted tubule, causing glucosuria. High-yield benefits: reduces heart failure hospitalizations and slows chronic kidney disease progression. Side effects include urinary tract infections, vulvovaginal candidiasis, and a risk of euglycemic DKA .
GLP-1 Receptor Agonists (e.g., Semaglutide): Mimics incretin to stimulate glucose-dependent insulin secretion, suppress glucagon, and delay gastric emptying. It reduces cardiovascular events and promotes weight loss. It is contraindicated in patients with a history of medullary thyroid cancer or MEN 2 .
Morning Hyperglycemia
To differentiate morning hyperglycemia, check a 3:00 AM blood glucose :
Dawn Phenomenon: Physiological early-morning surge of growth hormone/cortisol. 3:00 AM glucose is normal or elevated . Treatment: Increase bedtime basal insulin.
Somogyi Effect: Rebound hyperglycemia from nocturnal hypoglycemia. 3:00 AM glucose is low . Treatment: Decrease bedtime basal insulin or give a bedtime snack.
DKA vs. HHS Treatment Protocol
- Feature DKA Criteria HHS Criteria
- Glucose ≥ 200 mg/dL or known diabetes (euglycemic DKA < 200 in about 10%) > 600 mg/dL
- Arterial pH < 7.30 > 7.30
- Bicarbonate < 18 mEq/L > 18 mEq/L
- Ketones Positive Absent or minimal
- Osmolality Variable > 320 mOsm/kg
- Step-by-Step SIP Management
S - Saline (IV Fluids): Resuscitate with isotonic saline or a balanced crystalloid at 500–1,000 mL/hour for the first 2–4 hours (smaller 250 mL boluses in older adults, heart failure, or dialysis). When blood glucose falls below 250 mg/dL (in DKA) or to 300 mg/dL (in HHS), add 5–10% Dextrose to the fluids to prevent rapid glucose drops and cerebral edema.
I - Insulin Infusion: Give IV Regular insulin at 0.1 units/kg/hour. In DKA, continue until the ketoacidosis resolves: DKA is resolved when plasma ketone (β-hydroxybutyrate) is <0.6 mmol/L and venous pH is ≥7.3 or bicarbonate is ≥18 mEq/L (ideally glucose <200 mg/dL); the anion gap and urine ketones are not used as resolution criteria. In HHS, continue until osmolality normalizes.
P - Potassium Replacements: Insulin shifts potassium intracellularly, risking fatal arrhythmias. Check potassium before starting insulin:
Potassium < 3.5 mEq/L: HOLD INSULIN . Give IV potassium (about 10 mEq/hr) until potassium is > 3.5 mEq/L (2024 adult consensus).
Potassium 3.5–5.0 mEq/L: Give insulin and add 20–30 mEq of potassium to each liter of IV fluid.
Potassium > 5.0 mEq/L: Give insulin; start potassium once it falls below 5.0 (recheck 2 hours after insulin starts, then every 4 hours).
Classic PANCE Traps & Clinical Pearls
The Potassium Trap: Initiating insulin in DKA when potassium is < 3.5 mEq/L can cause life-threatening arrhythmias. You must correct potassium first.
Euglycemic DKA: SGLT2 inhibitors can cause DKA with normal or near-normal blood glucose. Check ketones in any patient on an SGLT2 inhibitor who presents with acidosis.